STOCK TITAN

Co-Diagnostics, Inc. to Present at 14th Next Generation Dx Summit in Washington, D.C.

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences

SALT LAKE CITY, Aug. 22, 2022 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq-CM: CODX) (the "Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that it will be sponsoring, presenting and hosting a booth this week at the 14th Annual Next Generation Dx Summit, held virtually and in-person in Washington, D.C. on August 22-24.

The Next Generation Dx Summit offers a valuable window into how point-of-care, infectious disease, liquid biopsy and companion diagnostics are changing the standard of care, and includes three streams: Point-of-Care and Infectious Disease, Companion Diagnostics and Reimbursement stream, and Liquid Biopsy and Early Detection. On Monday, August 22, at 12:15 PM ET, Company CEO Dwight Egan will be presenting on the Company's forthcoming Co-Dx PCR Home platform, in the conference's Enabling Point-of-Care diagnostics program.

In-person visitors are invited to visit the Company at Booth #206.

To learn more about the summit, including in-person and virtual registration details, please visit https://www.nextgenerationdx.com.

About Co-Diagnostics, Inc.:
Co-Diagnostics, Inc., a Utah corporation, is a molecular diagnostics company that develops, manufactures and markets state-of-the-art diagnostics technologies. The Company's technology is utilized for tests that are designed using the detection and/or analysis of nucleic acid molecules (DNA or RNA). The Company also uses its proprietary technology to design specific tests to locate genetic markers for use in industries other than infectious disease and license the use of those tests to specific customers.

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/co-diagnostics-inc-to-present-at-14th-next-generation-dx-summit-in-washington-dc-301609998.html

SOURCE Co-Diagnostics

Co-Diagnostics Inc

NASDAQ:CODX

CODX Rankings

CODX Latest News

CODX Stock Data

Surgical and Medical Instrument Manufacturing
Manufacturing
Link
Health Technology, Biotechnology, Manufacturing, Surgical and Medical Instrument Manufacturing
US
Salt Lake City

About CODX

co-diagnostics, inc. is a molecular diagnostics company that has acquired certain unique, patented diagnostic testing technology. a utah corporation headquartered in sandy, utah, its primary business is to commercialize its unique, patented technology through sales, development and licensing. the technology is embodied in three patent applications and certain trade secrets, which make dna testing for diseases faster, higher in performance, and more cost efficient than traditional technologies of the past. the company has undertaken completely innovative approaches to develop novel molecular technologies using biophysical models and statistical bioinformatics. it has successfully developed and commercialized a series of assays in the infectious disease area to demonstrate the capability of its technology. the technology on which the inventions are based were created by reference to certain mathematical models invented, designed and refined by dr. brent c. satterfield. the inventions are